Blood-based biomarkers for malignant gliomas

Matthias Holdhoff, Susannah G. Yovino, Osei Boadu, Stuart A Grossman

Research output: Contribution to journalArticle

Abstract

Malignant gliomas remain incurable and present unique challenges to clinicians, radiologists and clinical and translational investigators. One of the major problems in treatment of these tumors is our limited ability to reliably assess tumor response or progression. The most frequently used neuro-imaging studies (contrast-enhanced MRI and CT) rely on changes of blood-brain barrier (BBB) integrity, providing only an indirect assessment of tumor burden. In addition, the BBB can be altered by commonly used interventions including radiation, glucocorticoids and vascular endothelial growth factor inhibitors, further complicating the interpretation of scans. Newer radiologic techniques including PET and magnetic resonance spectroscopy are theoretically promising but thus far have not meaningfully changed the assessment of patients with malignant gliomas. A tumor-specific, blood-based biomarker would be of immediate use to clinicians and investigators if sufficiently sensitive and specific. This review discusses the potential utility of such a biomarker, the general classes of tumor-derived blood-based biomarkers and it summarizes the currently available data on circulating tumor cells, circulating nucleic acids and circulating proteins in patients with malignant gliomas. It is unclear which marker or marker class appears to be the most promising for these tumors. This article provides thoughts on how novel candidate blood-based markers could be discovered and tested in a more comprehensive way and why these efforts should be among the top priorities in neuro-oncologic research in the coming years.

Original languageEnglish (US)
Pages (from-to)345-352
Number of pages8
JournalJournal of Neuro-Oncology
Volume113
Issue number3
DOIs
StatePublished - Jul 2013

Fingerprint

Glioma
Biomarkers
Neoplasms
Blood-Brain Barrier
Research Personnel
Circulating Neoplastic Cells
Tumor Burden
Nucleic Acids
Vascular Endothelial Growth Factor A
Glucocorticoids
Magnetic Resonance Spectroscopy
Radiation
Research
Proteins
Therapeutics

Keywords

  • Blood-based biomarker
  • Circulating biomarker
  • Circulating tumor cells
  • Circulating tumor DNA
  • Glioblastoma
  • Malignant glioma
  • Pseudo-progression

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neurology
  • Medicine(all)

Cite this

Blood-based biomarkers for malignant gliomas. / Holdhoff, Matthias; Yovino, Susannah G.; Boadu, Osei; Grossman, Stuart A.

In: Journal of Neuro-Oncology, Vol. 113, No. 3, 07.2013, p. 345-352.

Research output: Contribution to journalArticle

Holdhoff, Matthias ; Yovino, Susannah G. ; Boadu, Osei ; Grossman, Stuart A. / Blood-based biomarkers for malignant gliomas. In: Journal of Neuro-Oncology. 2013 ; Vol. 113, No. 3. pp. 345-352.
@article{55e960e6cddd4a4da44e696ffd6ffee0,
title = "Blood-based biomarkers for malignant gliomas",
abstract = "Malignant gliomas remain incurable and present unique challenges to clinicians, radiologists and clinical and translational investigators. One of the major problems in treatment of these tumors is our limited ability to reliably assess tumor response or progression. The most frequently used neuro-imaging studies (contrast-enhanced MRI and CT) rely on changes of blood-brain barrier (BBB) integrity, providing only an indirect assessment of tumor burden. In addition, the BBB can be altered by commonly used interventions including radiation, glucocorticoids and vascular endothelial growth factor inhibitors, further complicating the interpretation of scans. Newer radiologic techniques including PET and magnetic resonance spectroscopy are theoretically promising but thus far have not meaningfully changed the assessment of patients with malignant gliomas. A tumor-specific, blood-based biomarker would be of immediate use to clinicians and investigators if sufficiently sensitive and specific. This review discusses the potential utility of such a biomarker, the general classes of tumor-derived blood-based biomarkers and it summarizes the currently available data on circulating tumor cells, circulating nucleic acids and circulating proteins in patients with malignant gliomas. It is unclear which marker or marker class appears to be the most promising for these tumors. This article provides thoughts on how novel candidate blood-based markers could be discovered and tested in a more comprehensive way and why these efforts should be among the top priorities in neuro-oncologic research in the coming years.",
keywords = "Blood-based biomarker, Circulating biomarker, Circulating tumor cells, Circulating tumor DNA, Glioblastoma, Malignant glioma, Pseudo-progression",
author = "Matthias Holdhoff and Yovino, {Susannah G.} and Osei Boadu and Grossman, {Stuart A}",
year = "2013",
month = "7",
doi = "10.1007/s11060-013-1144-0",
language = "English (US)",
volume = "113",
pages = "345--352",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Blood-based biomarkers for malignant gliomas

AU - Holdhoff, Matthias

AU - Yovino, Susannah G.

AU - Boadu, Osei

AU - Grossman, Stuart A

PY - 2013/7

Y1 - 2013/7

N2 - Malignant gliomas remain incurable and present unique challenges to clinicians, radiologists and clinical and translational investigators. One of the major problems in treatment of these tumors is our limited ability to reliably assess tumor response or progression. The most frequently used neuro-imaging studies (contrast-enhanced MRI and CT) rely on changes of blood-brain barrier (BBB) integrity, providing only an indirect assessment of tumor burden. In addition, the BBB can be altered by commonly used interventions including radiation, glucocorticoids and vascular endothelial growth factor inhibitors, further complicating the interpretation of scans. Newer radiologic techniques including PET and magnetic resonance spectroscopy are theoretically promising but thus far have not meaningfully changed the assessment of patients with malignant gliomas. A tumor-specific, blood-based biomarker would be of immediate use to clinicians and investigators if sufficiently sensitive and specific. This review discusses the potential utility of such a biomarker, the general classes of tumor-derived blood-based biomarkers and it summarizes the currently available data on circulating tumor cells, circulating nucleic acids and circulating proteins in patients with malignant gliomas. It is unclear which marker or marker class appears to be the most promising for these tumors. This article provides thoughts on how novel candidate blood-based markers could be discovered and tested in a more comprehensive way and why these efforts should be among the top priorities in neuro-oncologic research in the coming years.

AB - Malignant gliomas remain incurable and present unique challenges to clinicians, radiologists and clinical and translational investigators. One of the major problems in treatment of these tumors is our limited ability to reliably assess tumor response or progression. The most frequently used neuro-imaging studies (contrast-enhanced MRI and CT) rely on changes of blood-brain barrier (BBB) integrity, providing only an indirect assessment of tumor burden. In addition, the BBB can be altered by commonly used interventions including radiation, glucocorticoids and vascular endothelial growth factor inhibitors, further complicating the interpretation of scans. Newer radiologic techniques including PET and magnetic resonance spectroscopy are theoretically promising but thus far have not meaningfully changed the assessment of patients with malignant gliomas. A tumor-specific, blood-based biomarker would be of immediate use to clinicians and investigators if sufficiently sensitive and specific. This review discusses the potential utility of such a biomarker, the general classes of tumor-derived blood-based biomarkers and it summarizes the currently available data on circulating tumor cells, circulating nucleic acids and circulating proteins in patients with malignant gliomas. It is unclear which marker or marker class appears to be the most promising for these tumors. This article provides thoughts on how novel candidate blood-based markers could be discovered and tested in a more comprehensive way and why these efforts should be among the top priorities in neuro-oncologic research in the coming years.

KW - Blood-based biomarker

KW - Circulating biomarker

KW - Circulating tumor cells

KW - Circulating tumor DNA

KW - Glioblastoma

KW - Malignant glioma

KW - Pseudo-progression

UR - http://www.scopus.com/inward/record.url?scp=84879414694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879414694&partnerID=8YFLogxK

U2 - 10.1007/s11060-013-1144-0

DO - 10.1007/s11060-013-1144-0

M3 - Article

C2 - 23670054

AN - SCOPUS:84879414694

VL - 113

SP - 345

EP - 352

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -